© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
November 03, 2022
New details define the molecular patterns in thyroid eye disease and further implicate the role of insulin-like growth factor-1 in patients with low Clinical Activity Scores.
November 03, 2022
Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.
October 31, 2022
Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.
October 30, 2022
Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.
October 28, 2022
Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.
October 26, 2022
CEO Rob Thornhill discusses the features of the device, as well as plans for a new technology called ZEPTOLINK which combines the company’s novel ZEPTO technology with any phaco device.
October 26, 2022
Harit Bhatt, MD, a Chicagoland-area retinal surgeon, shared his experience with the LEAF and LION portable lasers during a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.
October 25, 2022
Vivek Patel, MD, discusses issues that could threaten sight during presentation at the American Academy of Ophthalmology annual meeting in Chicago.
October 25, 2022
Ula V. Jurkunas, MD, discusses a presentation she gave recently at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago on the use of limbal stem cells to treat corneal blindness.
October 21, 2022
Michelle Senchyna, PhD, provided an update of the COMET program and other development activities at Aerie Pharmaceuticals during a conversation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago.